Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Vascular

The catastrophic impact of COVID-19 infection in patients with chronic limb-threatening ischemia

Rafael de Athayde Soares, MD, PhD*, Nayara de Arruda Cáceres, MD, Anndya Gonçalves Barbosa, MD, Marcelo Fernando Matielo, MD, PhD, Roberto Sacilotto, MD, PhD

Division of Vascular and Endovascular Surgery, Hospital do Servidor Público Estadual de São Paulo, Brazil

Introduction

Since the outbreak of COVID-19 infections, it is well known that the virus affects disproportionately patients with cardiovascular disease.1,2 Furthermore, SARS-CoV-2, the causative agent of COVID-19, has been shown to establish itself in the host by exploiting angiotensin-converting enzyme 2 as its cellular receptor.3 Moreover, diabetes was present in 42.3% of 26 fatalities due to COVID-19 in Wuhan, China.4,5 Notwithstanding the COVID-19 pandemic, chronic limb-threatening ischemia (CLTI) continues to be a life-threatening condition, requiring appropriate intervention to avoid mortality and major amputations.6 The impact of COVID-19 infection on patients with CLTI has not yet been thoroughly studied in the literature. There are case reports in literature showing that patients with CLTI are linked to poorer prognosis when infected with SARS-CoV-2, due to medical comorbidities such as advanced age, hypertension, cardiovascular disease, and diabetes.7

* Reprint requests: Rafael de Athayde Soares, Av Ibirapuera, 981, Indianópolis 04028-000, São Paulo, SP, Brazil.
E-mail address: rafaelsoon@hotmail.com (R. de Athayde Soares).

https://doi.org/10.1016/j.surg.2021.10.016
0039-6060/© 2021 Elsevier Inc. All rights reserved.
Patients with COVID-19 infection are at risk of developing disseminated intravascular coagulation and thrombotic complications. There are studies reporting higher failure rate of revascularization surgery in patients with acute limb ischemia, CLTI, and COVID-19 pneumonia. Frequent early recurrent thrombosis and absence of forefoot microcirculation are also described as factors related to major amputations.

Therefore, the main objective of this study was to determine the impact of COVID-19 infection in patients with CLTI, mainly the limb salvage estimates rate and the overall survival.

Methods

Study design

The study was approved by the Ethical Committee for Research. All patients treated in our institution consented to the use of anonymized and aggregate data linked to the data basis for the purposes of research. No further patient contact was required. This was a retrospective, consecutive cohort study of CLTI patients with COVID-19 infection admitted at the Vascular and Endovascular Surgery Service of the Hospital do Servidor Público Estadual de São Paulo, between March 2020 and March 2021. Patient data were obtained from the service database using the Microsoft Access software. The patients’ medical records were also consulted as necessary. Information regarding the surgical procedures was obtained from the service database and the patients’ medical records.

Patients

Patients with COVID-19 infection, either symptomatic or asymptomatic, who were admitted with CLTI at our vascular surgery department. The patients were submitted either to revascularization (endovascular or open surgery), debridement, minor or major amputations and clinical treatment, depending on the clinical condition of the patient. Initial technical success of angioplasty was defined as no residual stenosis >30% or dissection at the end of the procedure, together with the prompt restoration of the circulation in the previously stenotic or occluded artery. Procedures such as debridement and minor amputations were performed, as necessary, during hospitalization. The COVID-19 infection was treated and controlled both by the vascular surgeon team and by the infectious disease team, and, if necessary, by the intensivist. All patients admitted at the hospital were submitted to reverse transcription polymerase chain reaction test for SARS-CoV-2. If necessary, serologic tests were performed for SARS-CoV-2. Patients with positive diagnostic for COVID-19 were systematically submitted to chest CT to stratify the pulmonary infection in less or more than 50% of the lungs, or normal. Aspirin at a dose of 100 mg/day and statins were prescribed for all patients before the procedures and continued after the endovascular surgery. Moreover, all patients submitted to endovascular therapy received clopidogrel with a loading dose of 300 mg immediately after the procedure and a maintenance dose of 75 mg/day for 6 months. Therapeutic anti-coagulation was administered according to COVID-19 infection and the patient’s clinical condition.

Wound, ischemia and foot infection classification

Wounds were classified according to the Society for Vascular Surgery wound, ischemia and foot infection (WIfI) classification system based on 2 blinded and independent providers consensus at initial presentation. The WIfI classification scores wounds on the basis of their wound, infection, and ischemia characteristics to generate a clinical stage that has been shown to correlate with wound healing.

The indications for angioplasty instead of bypass surgeries were essentially based on those defined by the TASC-II and the BASIL study (Bypass versus Angioplasty in Severe Ischaemia of the Leg) and based on the clinical condition of the patients. Patients with severe infection of COVID-19 were submitted to clinical treatment and, in cases of severe infection of the legs, to primary major amputation.

Major amputation was defined by amputation above the ankle. Debridements and minor amputations were performed when necessary. Dressings and antibiotics were administered for patients to treat their infection related to foot infection.

Outcomes

The primary outcome variable was the limb salvage rate and overall mortality. The secondary outcome variables were the factors related to overall mortality, prognosis of the COVID-19 infection and CLTI and factors related to limb loss.

Statistics

Statistical analyses were performed using SPSS 22.0 for Mac-Apple (SPSS Inc, Chicago, IL). The frequencies of patients and descriptive statistics were calculated. The χ² test or Student’s t test were used for univariate analyses. Analyses of the factors related to overall mortality rate and limb loss were made by univariate and multivariable analysis using logistic regression. Statistical significance was defined as a P value of < .05.

Results

All patients were evaluated during hospitalization until discharge or death. Overall, 35 patients with CLTI and COVID-19 infection were evaluated. The mean age of the patients was 72.51 years, and most of them were male (60%). Regarding the comorbidities, arterial hypertension was the most prevalent (85.7%), followed by diabetes mellitus (80%) and tobacco user (71.4%). There was a higher prevalence of WIfI classification 4 with 58.8% and Rutherford grade 5 (74.3%). All of those data are described in Table I.

| Variable         | Total (N = 35) |
|------------------|----------------|
| Age, years       | 72.51 ± 10.06  |
| Males            | 60%            |
| Hypertension     | 85.7%          |
| Diabetes         | 80%            |
| Heart disease    | 60%            |
| Chronic renal failure | 34.2%   |
| Claudication     | 44.1%          |
| WIfI 1           | 18 (51.4%)     |
| WIfI 2           | 1 (2.9%)       |
| WIfI 3           | 3 (8.8%)       |
| WIfI 4           | 20 (58.8%)     |
| Rutherford grade | 10 (29.4%)     |
| 4                | 3 (8.57%)      |
| 5                | 26 (74.3%)     |
| 6                | 6 (14.3%)      |

Regarding the type of treatment performed, 2 (5.7%) patients were submitted to open bypass surgery (1 iliacfemoral bypass with Dacron and 1 iliacfemoral bypass with basilic arm vein), 15 patients (44.1%) were submitted to endovascular treatment, 2 patients to a hybrid procedure (5.7%), 4 patients to debridements (11.4%), 5 patients to primary major amputations (14.3%) due to WIfI clinical
stage 5 (unsalvageable limb at presentation), and 7 patients submitted to a clinical treatment, without surgery (20.6%). The lesion location most prevalent were the toes, with 64.5% of cases. The overall mortality rate was 40%, and the major amputation rate was 23.5% (8 patients), transfemoral amputation 4 patients, and trans-tibial amputation 4 patients. A subanalysis was performed regarding the type of treatment and mortality rate. Among the 5 patients submitted to primary major amputations, the mortality rate was 80% (4 patients died); the patients submitted to clinical treatment had 42.9% mortality rate (3 patients died). Among the patients submitted to endovascular treatment, the mortality rate was 26.7% (4 patients), and in the open surgical group of patients, there were no deaths. All those data are summarized on Table II. Regarding the overall mortality rate, 100% of the patients died due to COVID-19 pneumonia infection. All patients who died with COVID-19 were ventilator dependent.

Regarding the COVID-19 infection, 18 patients (52.9%) had reverse transcription polymerase chain reaction test for SARS-CoV-2 positive. Twenty-three patients (65.7%) had a serology immunoglobulin M (IgM) positive, and 12 patients (34.3%) had a serology immunoglobulin G (IgG) positive. Eightteen patients (51.4%) had respiratory symptoms, and 10 patients (28.6%) had a chest CT showing pulmonary infection comprising >50% of the lungs. Five patients (14.3%) presented acute kidney failure, needing hemodialysis. There were 33 patients (94.3%) who received any kind of anticoagulant drug, most of them endovenous unfractionated heparin (17 patients, 51.5%), and therapeutic anticoagulation was administered for 5 patients (14.3%). Moreover, 11 patients (31.4%) received endovenous dexamethasone. D-dimer was higher than 1,000 mg/dL in 18 patients (51.4%), mean 1,521 mg/dL. Those data are summarized in Table III.

A univariate and multivariate logistic regression analysis was performed to analyze the factors related to overall mortality. Among the factors evaluated, the following were related to overall mortality rate: D-dimer >1,000 mg/dL (HR = 22.7, P < .001, CI = 10.49–26.52), respiratory symptoms (HR = 16.6, P < .001, CI = 9.87–20.90), chest CT compromising higher than 50% of the pulmonary tract (HR = 16.0, P < .001, CI = 10.41–20.55), acute kidney failure (HR = 21.58, P < .001, CI = 16.5–30.5), chronic kidney disease (HR = 4.4, P = .036, CI = 1.45–10.1), therapeutic anticoagulation (HR = 8.37, P = .004, CI = 1.35–8.45), and WIfI classification (HR = 5.28, P = .022, CI = 1.34–10.01). These data are summarized in Table IV.

Patients with WIfI 3–4 had higher mortality rate than WIfI 1–2 (38.2% vs 2.9%, P = .009), in a crosstabs analysis. Furthermore, patients who received therapeutic anticoagulation had higher mortality rate than patients who received prophylactic doses (100% vs 30%, P = .006), in a crosstabs analysis. Among the patients with D-dimer higher than 1,000 mg/dL, 88.9% had pulmonary symptoms (P < .001), and 55.6% had chest CT showing pulmonary infection compromising >50% of the lungs (P = .001).

Regarding major amputation rates, patients with WIfI 3–4 had higher incidence rates than WIfI 1–2 (27.5% vs 0%, P = .01). Furthermore, D-dimer >1,000 mg/dL was also related to higher amputation levels than D-dimer <1,000 mg/dL (20.6% vs 2.9%, P = .018), in a crosstabs analysis. Among the patients submitted to endovascular treatment, there was a 13.3% major amputation rate (2 patients); in the surgical group of patients, there were no major amputations, and in the clinical group of patients, there was a 14.2% major amputation rate (1 patient).

Moreover, a univariate and multivariate logistic regression also was performed to test the factors related to major amputation rate. Among the factors evaluated, the following were related to limb loss: D-dimer >1,000 mg/mL (HR = 5.47, P = .02, CI = 1.94–10.52), respiratory symptoms (HR = 5.42, P = .02, CI = 1.87–10.90), and WIfI classification (HR = 4.44, P = .035, CI = 1.34–8.01). These data are summarized in Table V.

We have performed a control group with CLTI patients treated during the same timeframe 1 year before the onset of the COVID pandemic in our vascular department; 95 infrapopliteal endovas-cular procedures were performed in 95 patients. The mean age was 72.97 ± 8.3 years, with higher prevalence of male gender (55.6%). Regarding the WIfI classification subanalysis, there were 22 patients WIfI 1–2 (23.2%) and 73 patients WIfI 3–4 (76.8%). The overall mortality rate was 2.1%. The limb salvage rate at 360 days was 92.6%. A simple comparison among this present study, showing a 40% overall mortality rate, demonstrates an almost 20-fold increase in mortality rate, and a major amputation rate of 23.5%, demonstrating a 3-fold increase in limb loss rate with the same period 1 year before the COVID-19 pandemic crisis.

Discussion

The recent COVID-19 pandemic has significantly increased pressure on the healthcare system around the world, leading to important changes in the treatment of patients without COVID–19, resulting in the most difficult access to care with delays in diagnosis and treatment.10 Especially patients with CLTI require rapid revascularization to avoid tissue loss and amputation. Some publications reported that the number of amputations performed in
2020 was significantly greater than the number performed in the same period in 2019, an increase of almost 50%. Similarly, in this present article we have noticed an increase in amputation rate, higher than 50%, when compared to past articles published in our department in 2016, 2018, and 2019 (23.5%; 7.7%, 10%, 11%). The possible explanation to this increased amputation rate may be related to an introduction of the lockdown in Brazil, which led to the closure of outpatient activities and prevented early observation of patients with CLTI. Patients arrived with more severe forms of CLTI, such as septic ulcers and gangrene, at our vascular surgery department. Furthermore, COVID-19 infection is related to thrombotic complications. Patients infected by this disease are at risk of developing disseminated intravascular coagulation. Increased levels of D-dimer and fibrin degradation products and prolonged prothrombin time have been associated with poor prognosis in patients affected by the novel coronavirus. Similarly, in this present study, D-dimer >1,000 mg/dL was related to higher major amputation rates than D-dimer <1,000 mg/dL (20.6% vs 2.9%, P = .018). These patients had more severe clinical conditions; some of them were submitted to primary major amputation, without attempt for revascularization, due to high risk and irreversible conditions of the limbs. Another factor related to major amputation rate in this present study was WIfI 3-4, both in a crosstab analysis and in a logistic regression. Those data are comparable with overall literature, especially in patients with COVID-19 infection, whose severe clinical conditions make the revascularization procedures and limb salvage even more difficult. In the overall literature, the WIfI classification was considered more important to limb salvage rates and ulcer/wound healing rates than angiographic concept. Moreover, the WIfI classification 1-2 was associated with faster and higher wound/ulcer healing rates than WIfI classification 3-4. The time to heal the ulcer was faster in the WIfI 1-2 groups than WIfI 3-4 groups (164.82 days vs 251.48; P = .017). Furthermore, WIfI stage is strongly associated with wound healing, improvement of Rutherford stage, amputation rate, and long-term mortality. In patients with COVID-19 and concomitant CLTI, the WIfI stage continues to be a predictor or mortality and major amputations.

Another result that needs further discussion is the high overall mortality rate among patients with CLTI and COVID-19 infection. D-dimer >1,000 mg/dL and therapeutic anticoagulation were associated with overall mortality rate (HR = 22.7, P < .001, CI = 10.49–26.52; HR = 8.37, P = .004, CI = 1.35–8.35, respectively). Reported evidence of coagulopathy in COVID-19 infection showed increased levels of D-dimer, lactate dehydrogenase, mild to no changes in PT and PTT, and increased levels of antiphospholipid antibodies. A recent systematic review showed that elevated levels of D-dimer in patients with COVID-19 are associated with poor prognosis. According to this study, the latest literature review suggests that the D-dimer test can be a reliable predictor of thrombosis growth in COVID-19 and its prognosis. Similarly, therapeutic anticoagulation in this present study was associated with a higher mortality. These findings are similar to those found by Lopes et al., in a study comparing the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalized with COVID-19. The authors concluded that in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. Therefore, use of therapeutic-dose rivaroxaban, and other direct oral anticoagulants, should be avoided in these patients in the absence of an evidence-based indication for oral anticoagulation. Furthermore, the higher mortality rate associated with patients under therapeutic anticoagulation should be explained by the severe clinical condition of these patients and the pro-coagulation clinical status. Another factor related to overall mortality rate in the present article was acute and chronic kidney failure (HR = 21.58, P < .001, CI = 16.5–30.5; HR = 4.4, P = .036, CI = 1.45–10.1). These data regarding kidney dysfunction and COVID-19 infection mortality rate are comparable with the global literature. A recent meta-

### Table IV
Logistic regression analysis of factors associated with overall mortality rate

| Variable | Univariate analysis | Multivariate analysis |
|----------|---------------------|-----------------------|
|          | B | HR | 95% CI | P  | B | HR | 95% CI | P  |
| Rutherford classification | 0.988 | 0.065 | 0.330–2.760 | .931 | 0.597 | 0.065 | 0.226–10.060 | .880 |
| D-dimer >1,000 mg/dL | 1.805 | 22.7 | 10.49–26.52 | <.001 | 1.296 | 22.7 | 10.49–26.52 | <.001 |
| Chronic kidney disease | 1.592 | 4.40 | 1.45–10.1 | .036 | 2.592 | 4.40 | 1.45–10.1 | .036 |
| Diabetes | 0.546 | 0.220 | 0.341–1.272 | .339 | 0.564 | 0.220 | 0.311–14.294 | .339 |
| WIfI classification | 3.047 | 5.280 | 1.34–10.01 | .022 | 4.089 | 5.280 | 1.34–10.01 | .022 |
| Acute kidney failure | 2.285 | 5.422 | 1.98–20.90 | <.001 | 2.185 | 5.422 | 1.98–20.90 | <.001 |
| Therapeutic anticoagulation | 1.888 | 16.0 | 10.41–20.55 | <.001 | 1.978 | 16.0 | 10.41–20.55 | <.001 |
| Respiratory symptoms Chest CT >50% | 2.907 | 21.58 | 16.5–30.5 | <.001 | 2.796 | 21.58 | 16.5–30.5 | <.001 |
| Acute kidney failure | 20.220 | 8.370 | 1.35–8.45 | .004 | 20.220 | 8.370 | 1.35–8.45 | .004 |

CI, confidence interval; CT, computed tomography; HR, hazard ratio.

### Table V
Logistic regression analysis of factors associated with limb loss

| Variable | Univariate analysis | Multivariate analysis |
|----------|---------------------|-----------------------|
|          | B | HR | 95% CI | P  | B | HR | 95% CI | P  |
| Rutherford classification | 0.988 | 0.065 | 0.330–2.760 | .931 | 0.597 | 0.065 | 0.226–10.060 | .880 |
| D-dimer >1,000 mg/dL | 3.085 | 5.47 | 1.94–10.52 | .02 | 3.296 | 5.47 | 1.94–10.52 | .02 |
| Chronic kidney disease | 3.582 | 0.220 | 0.45–10.1 | .89 | 0.592 | 0.40 | 0.45–10.1 | .98 |
| Diabetes | 1.646 | 1.220 | 0.341–1.272 | .339 | 1.564 | 1.220 | 0.311–14.284 | .339 |
| WIfI classification | 3.047 | 4.40 | 1.34–8.01 | .035 | 5.089 | 4.40 | 1.34–8.01 | .035 |
| Respiratory symptoms Chest CT >50% | 4.286 | 5.420 | 1.87–10.90 | .02 | 4.185 | 5.420 | 1.87–10.90 | .02 |
| Acute kidney failure | 2.888 | 0.898 | 0.41–20.55 | .78 | 12.978 | 16.0 | 0.41–20.55 | .78 |
| Acute kidney failure | 3.907 | 1.58 | 0.65–30.5 | .98 | 1.796 | 0.220 | 0.509–3.5 | .98 |

CI, confidence interval; HR, hazard ratio.
analysis by Ali et al.\textsuperscript{22} showed that mortality is significantly higher in patients with COVID-19 with severe acute kidney injury. According to this meta-analysis, acute kidney injury stage III occurred in 14/701 (2\%) of the patients and was associated with an increased risk of in-hospital mortality (hazard ratio $= 9.81$, 95\% CI 5.46–17.65). Another meta-analysis\textsuperscript{23} showed significant association of chronic kidney disease with severe COVID-19, with no relevant heterogeneity (OR 3.03 [95\% CI 1.09–8.47], I$^2 = 0\%$). Cochran’s Q, $P = 0.84$). The authors concluded that chronic kidney disease should be regarded as an important factor in future risk stratification models for COVID-19.

In the present study, overall mortality was 40\%, and patients with chest CT scan showing severe pulmonary disease and pulmonary symptomatic patients were related to overall mortality in a logistic regression analysis. These data are similar to those found in several studies in literature,\textsuperscript{21,24} especially a Brazilian study among 250,000 patients hospital admissions for COVID-19. The authors showed that in-hospital mortality was 38\% (87,515 of 232,036 patients) overall, 59\% (47,002 of 79,687) among patients admitted to the ICU, and 80\% (36,046 of 45,205) among those who were mechanically ventilated. Moreover, in-hospital mortality among patients younger than 60 years was 31\% (4,204 of 13,468) in the Northeast versus 15\% (1694 of 11196) in the South.

This study has some limitations, mainly the sample size and noncomparable analysis with patients with CLI and nonconcomitant COVID-19 infection. Notably, very few studies have analyzed the impact of COVID-19 infection among patients with CLI.

In conclusion, this study concluded that COVID-19 has a catastrophic impact among patients with CLI. The main factors related to overall mortality were D-dimer >1,000 mg/dL, respiratory symptoms, chest CT compromising higher than 50\% of the pulmonary tract, acute kidney failure, chronic kidney disease, therapeutic anticoagulation, and WIfI classification. The factors related to limb loss were WIfI classification, D-dimer >1,000 mg/mL, and respiratory symptoms.

Funding/Support

None disclosed.

Conflict of interest/Disclosure

There is no conflict of interest in the present study.

References

1. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–848.
2. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802.
3. Iida O, Soga Y, Hirako K, et al. Long-term results of direct and indirect endovascular revascularization based on the angiosome concept in patients with critical limb ischemia presenting with isolated below-the-knee lesions. J Vasc Surg. 2012;55:363–370.
4. Hoffmann M, Kleine-Wieber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;18:271–280.e8.
5. Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9:575.
6. Soares RA, Vedovello RS, Medeiros SGC, Nunes CZ, Sian CA, Jorge PDM. COVID-19 diagnosis in a patient with critical limb ischemia: complications and clinical outcomes. J Vasc Bras. 2020;19:e20200071.
7. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for COVID-19: clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
8. Bellotta R, Luzzani L, Natalini G. Acute limb ischemia in patients with COVID-19 pneumonia. J Vasc Surg. 2020;72:1864–1872.
9. Weaver ML, Hicks CW, Canner JK, et al. The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system predicts wound healing better than direct angiography perfusion in diabetic foot wounds. J Vasc Surg. 2018;68:1473–1481.
10. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S), S1–S109.e33.
11. Sena G, Gallelli G. An increased severity of peripheral arterial disease in the COVID-19 era foot wounds. J Vasc Surg. 2020;72:758.
12. De Athayde Soares R, Matielo MF, Brochado-Neto FC, et al. WIfI classification versus angiosome concept: a change in the infrapopliteal angioplasties paradigm. Ann Vasc Surg. 2021;71:338–345.
13. de Athayde Soares R, Matielo MF, Brochado Neto FC, et al. Impact of calcification and infrapopliteal outflow on the outcome of endovascular treatment of femoropopliteal occlusive disease. JRS Cardiovasc Dis. 2019;8:204800419828941.
14. de Athayde Soares R, Matielo MF, Brochado Neto FC, Martins Cury MV, Marques RC, Sacilotto R. Number of infrapopliteal arteries undergoing endovascular treatment is not associated with the limb salvage rate in patients with critical limb ischemia. J Vasc Surg. 2016;64:1344–1350.
15. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847.
16. Mills Jr JL, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59:220–234.e1–2.
17. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S), S1–S125.e8.
18. Shi C, Wang C, Wang H, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. medRxiv. 2020.2020.03.28.20046144.
19. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382:e38.
20. Rostami M, MansouriTorghabeh H. D-dimer level in COVID-19 infection: a systematic review and meta-analysis. J Thromb Haemost. 2020;18:2263.
21. Lopes RD, Furtado RHM, Macedo AVS, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2020;397:2253–2263.
22. Ali H, Daoud A, Mohamed MM, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren Fail. 2020;42:393–397.
23. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020;1–2.
24. Bhaskaran K, Bacon S, Evans SJW, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet. 2021;5:1001–1009.